Axonyx Reports Results Encouraging in Trial of Phenserine

A phase II clinical trial of Phenserine, an acetylcholinesterase inhibitor, showed that it appears to improve memory and cognition in patients with mild to moderate Alzheimer's disease, according to Axonyx.

The safety results from the study of 72 patients with mild to moderate Alzheimer's disease also showed the drug to be safe and well tolerated, the company said.

"Based on current analysis, we are very encouraged," said Dr. Marvin S. Hausman, Chief Executive Officer of Axonyx. "The results clearly suggest that Phenserine is at least as safe and well tolerated as currently marketed products and, in a clinical trial not designed to reveal clinical efficacy, our drug improved memory and cognition in mild to moderate Alzheimer's disease patients."

Other sources: Axonyx